Exosomes Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight's, "Exosomes Pipeline Insight 2025" report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in Exosomes pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Exosomes Pipeline. Dive into DelveInsight's comprehensive report today! @ Exosomes Pipeline Outlook [https://www.delveinsight.com/sample-request/exosomes-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Exosomes Pipeline Report

* In April 2025, Aegle Therapeutics announced a study, with intra-subject paired- wound control, intended to assess the safety and preliminary efficacy of administering EVs derived from allogeneic MSCs to 10-50 cm2 wounds in RDEB subjects with wounds persisting for at least four weeks.
* DelveInsight's Exosomes pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for Exosomes treatment.
* The leading Exosomes Companies such as Capricor Therapeutics, Regeneus, Aegle Therapeutics, Innovex Therapeutics, Coya Therapeutics, EV Therapeutics, StemXO Therapeutics, Brexogen, ILIAS Biologics, Organicell Regenerative Medicine, Codiak BioSciences, Direct Biologics , and others.
* Promising Exosomes Pipeline Therapies such as Anlotinib, AGLE 102, TISSEEL , and others.

Stay ahead with the most recent pipeline outlook for Exosomes. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Exosomes Treatment Drugs [https://www.delveinsight.com/sample-request/exosomes-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Exosomes Emerging Drugs Profile

* ExoFlo: Direct Biologics

ExoFlo is an acellular human bone marrow mesenchymal stem cell (MSC) derived extracellular vesicle (EV) product produced with a proprietary EV platform technology by Direct Biologics, LLC. Containing signaling molecules from bone marrow MSCs, ExoFlo harnesses the anti-inflammatory and regenerative properties of bone marrow MSCs without the cost, complexity, and limitations of scale associated with stem cell transplantation.

* EXO-CD24: Nano24

EXO-CD24 (CovenD24), is an investigational drug being developed by Nano24. The company has developed a new anti-inflammatory drug, EXO-CD24, a combination of an immune checkpoint (CD24) and a delivery platform (exosomes). CD24 inhibits the NF-kB pathway and the production of cytokines/chemokines. EXO-CD24 discriminates damage from pathogen-associated molecular patterns (DAMPs and PAMPs) and therefore does not interfere with viral clearance. EXO-CD24 was produced and purified from CD24-expressing 293-TREx cells. Exosomes displaying murine CD24 (mCD24) were also created.

* AGLE-102: Aegle Therapeutics

AGLE 102 is an allogeneic-derived extracellular vesicle (EV) product derived from normal donor mesenchymal stem cells (MSCs). AGLE-102 is a composite of mesenchymal stem cell-derived extracellular vesicles that deliver proteins, genetic material, and regenerative healing factors to diseased and damaged tissue. The drug is being developed in the Phase I/II stage of its development for the treatment of Burns and Epidermolysis bullosa dystrophica. The drug is also in the preclinical stage of its development for the Graft vs. Host Disease.

* Progenza: Cambium Bio

Progenza is an off-the-shelf allogeneic stem cell product with the first targeted treatment being for knee osteoarthritis. The product is produced from mesenchymal stem cells (MSCs) from adipose (fat) tissue from a healthy donor who has been extensively screened. Progenza includes secretions from donor MSCs that improves viability and functionality of the cells after freezing. Adipose tissue is readily available from donors in large quantities and has significantly higher MSCs per gram of tissue than other tissue sources such as bone marrow or cord tissue. Adipose-derived MSCs also have the added advantage of showing greater capacity for expansion than MSCs from other tissue types.

* EV-101: EV Therapeutics

EV Therapeutics is a pre-clinical stage immuno-oncology biotechnology company devoted to developing first-in-class therapies based on modified tumor extracellular vesicles (mTEVs) to significantly transform cancer therapy and other unmet medical needs that are addressable with its proprietary technology platform. The leading candidate EV101, has demonstrated pre-clinical efficacy across solid tumor and advanced metastatic animal models both as a monotherapy and combination therapy with checkpoint inhibitors.

The Exosomes Pipeline Report Provides Insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of Exosomes with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Exosomes Treatment.
* Exosomes Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Exosomes Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Exosomes market

Explore groundbreaking therapies and clinical trials in the Exosomes Pipeline. Access DelveInsight's detailed report now! @ New Exosomes Drugs [https://www.delveinsight.com/sample-request/exosomes-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Exosomes Companies

Capricor Therapeutics, Regeneus, Aegle Therapeutics, Innovex Therapeutics, Coya Therapeutics, EV Therapeutics, StemXO Therapeutics, Brexogen, ILIAS Biologics, Organicell Regenerative Medicine, Codiak BioSciences, Direct Biologics, and others.

Exosomes Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical

Exosomes Products have been categorized under various Molecule types such as

* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy

Unveil the future of Exosomes Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Exosomes Market Drivers and Barriers [https://www.delveinsight.com/sample-request/exosomes-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Exosomes Pipeline Report

* Coverage- Global
* Exosomes Companies- Capricor Therapeutics, Regeneus, Aegle Therapeutics, Innovex Therapeutics, Coya Therapeutics, EV Therapeutics, StemXO Therapeutics, Brexogen, ILIAS Biologics, Organicell Regenerative Medicine, Codiak BioSciences, Direct Biologics , and others.
* Exosomes therapies- Anlotinib, AGLE 102, TISSEEL, and others.
* Exosomes Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Exosomes Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Exosomes Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Exosomes Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/exosomes-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Executive Summary
* Exosomes : Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Exosomes - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* CAP-1002: Capricor Therapeutics
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Progenza: Regeneus
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I/II)
* AGLE 102: Aegle Therapeutics
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* Exosomes Key Companies
* Exosomes Key Products
* Exosomes - Unmet Needs
* Exosomes - Market Drivers and Barriers
* Exosomes - Future Perspectives and Conclusion
* Exosomes Analyst Views
* Exosomes Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=exosomes-pipeline-appears-robust-with-100-key-pharma-companies-actively-working-in-the-therapeutics-segment-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/exosomes-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.